Prevalencia de fibrosis hepática estimada por predictor no invasivo en una población de pacientes con Diabetes Mellitus Tipo 2

Abstract

 Metabolic associated fatty liver disease (MAFLD) is currently a public health issue, defined as macrovesicular steatosis in at least 5% oh hepatocytes in the absence of alcohol consumption. MAFLD is the hepatic manifestation of Metabolic Syndrome and includes both steatosis and steatohepatitis with its risk of developing fibrosis and eventually liver cirrhosis and hepatocellular carcinoma. Diabetes is considered a risk factor the development of MAFLD. The aim of our study is to determine the prevalence of fibrosis determined by noninvasive methods in a population of patients with diabetes included in the CUIDATE program of Clinical Internacional. Materials and methods: We conducted a cross sectional study during the year 2021. Clinical records of patients with diabetes were reviewed. Patients with CBC and liver function tests were included. BMI and FIB-4 were calculated. Results: 235 patients were selected, of which 58.7% (138) were male, while 41.27% (97) were female; with an average age of 57.6 years. 80.85% (190) of the patients had a BMI greater than 25 kg/ m2. Significant fibrosis (F2) was estimated by calculating FIB-4 in 28.9% (68) and advanced fibrosis in 2.97% (7) of the patients. Conclusions: Patients with type 2 diabetes mellitus in the Cuídate Program have an estimated prevalence using the non-invasive predictor FIB-4 of significant liver fibrosis of 28.9% and advanced fibrosis of 2.97%.